Association and clinical utility of \textit{NAT2} in the prediction of isoniazid-induced liver injury in Singaporean patients

Sze Ling Chan\textsuperscript{1}, Angeline Poh Gek Chua\textsuperscript{2}, Folefac Aminkeng\textsuperscript{1}, Cynthia Bin Eng Chee\textsuperscript{2}, Shengnan Jin\textsuperscript{3}, Marie Loh\textsuperscript{1}, Suay Hong Gan\textsuperscript{2}, Yee Tang Wang\textsuperscript{2}, Liam R. Brunham\textsuperscript{1,4*}

\textsuperscript{1} Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research, Singapore and the National University of Singapore, Singapore, \textsuperscript{2} Department of Respiratory Medicine, Tan Tock Seng Hospital, Singapore, \textsuperscript{3} School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China, \textsuperscript{4} Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada

* liam.brunham@ubc.ca

Abstract

Background and aims

Isoniazid (INH) is part of the first-line-therapy for tuberculosis (TB) but can cause drug-induced liver injury (DILI). Several candidate single nucleotide polymorphisms (SNPs) have been previously identified but the clinical utility of these SNPs in the prediction of INH-DILI remains uncertain. The aim of this study was to assess the association between selected candidate SNPs and the risk of INH-DILI and to assess the clinical validity of associated variants in a Singaporean population.

Methods

This was a case-control study where 24 INH-DILI cases and 79 controls were recruited from the TB control unit in a tertiary hospital. Logistic regression was used to test for the association between candidate SNPs and INH-DILI. NAT2 acetylator status was inferred from genotypes and tested for association with INH-DILI. Finally, clinical validity measures were estimated for significant variants.

Results

Two SNPs in \textit{NAT2} (rs1041983 and rs1495741) and NAT2 slow acetylators (SA) were significantly associated with INH-DILI (OR (95\% CI) = 13.86 (4.30–44.70), 0.10 (0.03–0.33) and 9.98 (3.32–33.80), respectively). Based on an INH-DILI prevalence of 10\%, the sensitivity, specificity, positive and negative predictive values of NAT2 SA were 75\%, 78\%, 28\% and 97\%, respectively. The population attributable fraction (PAF) and number needed to test (NNT) for NAT2 SA were estimated to be 0.67 and 4.08, respectively. A model with clinical and NAT2 acetylator status provided significantly better prediction for INH-DILI than a clinical model alone (area under receiver operating characteristic curve = 0.863 vs. 0.766, respectively, p = 0.027).
Conclusions

We show the association between NAT2 SA and INH-DILI in a Singaporean population and demonstrated its clinical utility in the prediction of INH-DILI.

Introduction

Tuberculosis (TB) is one of the top 10 causes of death world-wide, with an estimated 10.4 million new cases and 1.8 million TB-related deaths worldwide in 2015 [1]. Isoniazid (INH) is an effective anti-mycobacterium agent and is part of first-line 4-drug therapy for TB that also includes rifampicin, pyrazinamide and ethambutol [1]. However, INH is associated with drug-induced liver injury (DILI) that can range from asymptomatic elevations in liver enzymes in 10–20% of patients, to clinically significant hepatitis and acute liver failure in 0.5–1% of patients [2]. Risk factors for INH-DILI include age, female gender, black race, alcoholism, pre-existing liver disease, and concomitant medications such as rifampicin and pyrazinamide [2].

The molecular mechanisms of anti-TB DILI are not fully understood, but it is thought accumulation of toxic intermediate metabolites plays an important role [3]. Pharmacogenomic studies have been mainly focused on candidate genes involved in INH biotransformation and metabolism, including N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1) and glutathione-S-transferase genes (GSTT1, GSTM1 and GSTP1). In addition, INH and some of its metabolites are readily oxidized to reactive species, which may contribute to liver damage [4]. INH-DILI typically occurs within 2 weeks to 6 months after commencing therapy [2]. The delayed nature of INH-DILI also points to a possible immune component [4]. As such, genes in the antioxidant and detoxification pathways [5–8], human-leukocyte antigen system [9,10] and tumor necrosis factor-α [11] have also been studied.

Meta-analyses have consistently shown that NAT2 slow acetylators (SA) have a higher risk of INH-DILI, with an odds ratio (OR) of around 3.1 [12,13]. Seven common coding single nucleotide polymorphisms (SNPs) (rs1801279, rs1041983, rs1801280, rs1799929, rs1799930, rs1208 and rs1799931) define 34 haplotypes, but most studies only genotype a subset to infer acetylator status [14]. Recently, a tag SNP, rs1495741, located 14.5kb 3’ of NAT2 has been associated with INH-DILI, although it may not be a good surrogate for acetylator status [14,15].

In CYP2E1, two polymorphisms are most commonly studied (Rsal/PstI (rs2031920/rs3813867) and DraI (rs6413432)). rs2031920 and rs3813867 are in complete linkage disequilibrium in East Asians [16]. A recent meta-analysis found that the Rsal/PstI polymorphism c1/c1 (major allele for both SNPs) confers a higher risk of INH-DILI with an OR of 1.32 compared to the c1/c2 or c2/c2 genotypes, but no increase in risk for the DraI polymorphism [16].

These candidate SNPs have been studied in diverse populations including several of Asian descent (Chinese, Xinjiang Uyghurs, Japanese, Korean, Indian, Taiwanese and Indonesian) [15,17–39]. However, no previous study has been conducted in a Singaporean population. The 3 major ethnic groups in Singapore, Chinese, Malays and Indians, originated largely from Southern China, Peninsula Malaysia and Indonesia, and Southern India, respectively [40]. Results derived from the Singaporean population may therefore have broad applicability to populations that have not been well represented in previous candidate gene studies. Malays in particular, have not been included in INH-DILI studies apart from one focused on NAT2 [35]. Representation of these populations is crucial since India, China and Indonesia are among the countries with the greatest burden of TB burden worldwide [1].
To facilitate the clinical implementation of prospective pharmacogenomic screening for INH-DILI in these South and Southeast Asian countries, it is imperative to determine the genetic and clinical relevance of INH-DILI pharmacogenomic biomarkers in representative populations. Therefore, the objective of this study was to assess the association between selected candidate SNPs and the risk of INH-DILI, and to assess the clinical validity of associated variants in a multiethnic Singaporean population representative of the Southeast Asian region.

**Results**

**Clinical and demographic characteristics**

A total of 104 patients were recruited (S1 Fig). One patient failed genotyping quality control (QC) due to sex mismatch, leaving 103 patients (24 cases and 79 controls) for analysis. No samples were removed due to high identity-by-state (IBS). The clinical characteristics of cases and controls are shown in Table 1. Most cases had grade 2 (41.7%) or grade 3 (54.2%) INH-DILI and only 1 patient had grade 4 INH-DILI. The median onset time for INH-DILI was 17.5 days (range 4–111 days), which is consistent with the typical onset time of 2 weeks to 6 months [2]. Cases were more likely to be female than controls (p = 1.80 x 10^{-3}) and were more likely to be of ‘Other’ ethnicity (Table 1).

After removing SNPs with call rate <95% or deviation from Hardy-Weinberg Equilibrium (HWE) within Chinese patients, 536859 SNPs remained. Principal components analysis (PCA) performed using our genome-wide SNP data showed distinct clustering according to self-reported ethnicity, except for ‘Others’ which was spread between the Chinese and Malay clusters (S2 Fig). Although Mann-Whitney U tests on the first 10 principal components (PCs) by case control status were not statistically significant, we used the first 2 PCs to adjust for ethnic differences in subsequent analyses based on the fact that there were different ethnicities in our cohort, scree plot of the eigenvalues (S3 Fig) and visual inspection of PCA plot (S2 Fig).

**Pharmacogenomic association analysis**

We performed a comprehensive literature review of INH-DILI and identified 20 candidate SNPs with prior evidence of association with INH-DILI, minor allele frequency (MAF) > 0.05 in at least 1 population and present in our genotyping panel (S1 Table), which we tested for association in our cohort. Of these 20 candidate SNPs, 2 SNPs (rs1041983 and rs1495741), both in the NAT2 gene, were significantly associated with INH-DILI in our cohort after correction for multiple correlated tests. The recessive model was most significant for rs1041983 (OR (95% confidence interval (CI)) = 13.86 (4.30–44.70), adj P = 4.754 x 10^{-4}), whereas the dominant model was most significant for rs1495741 (OR (95% CI) = 0.10 (0.03–0.33), adj P = 0.004) (Table 2 & S2 Table). Analyses using the first 5 PCs, 20 PCs or self-reported ethnicity instead of the first 2 PCs yielded very similar results. Association with INH-DILI severity by ordinal logistic regression also yielded very similar results (S3 Table). Cluster plots of these 2 SNPs showed clear clustering of genotypes (S4 Fig).

We next inferred acetylator phenotype using a 4 SNP panel, which did not include either of the 2 significant SNPs [14]. Thirty-five patients (34%) were predicted to be SA. SA status was significantly associated with INH-DILI compared to intermediate acetylator (IA) + rapid acetylator (RA) (OR (95% CI) = 9.98 (3.32–33.80), logistic regression p = 8.36 x 10^{-5}). Results from Fisher’s exact test were similar (S4 Table). The frequencies of the risk alleles showed an increasing trend with DILI grade (Fig 1).
Genetic associations may be specific to certain populations. To determine if the associations we observed were consistent across all ethnic groups, we also explored the association between NAT2 acetylator status and the 2 significant SNPs within the 3 major ethnic groups in our cohort. The effect sizes remained similar in Chinese but were smaller and consistent in direction in Malays and Indians (S5 Table).

Table 1. Demographic and clinical characteristics of Singaporean patients diagnosed with TB and treated with INH.

| Clinical and Demographic Characteristics | All Patients (n = 103) | INH-DILI Cases (n = 24) | Controls (n = 79) | P value* |
|----------------------------------------|------------------------|-------------------------|------------------|----------|
| Age, mean (sd)                         | 51.1 (14.5)            | 51.6 (16.8)             | 50.9 (13.9)      | 0.728†   |
| Male gender, n (%)                     | 68 (66.0)              | 9 (37.5)                | 59 (74.7)        | 1.80 x 10⁻³¹ |
| Ethnicity, n (%)                       |                        |                         |                  | 0.034†   |
| Chinese                                | 69 (67.0)              | 12 (50.0)               | 57 (72.2)        | 0.051†   |
| Malays                                 | 15 (14.6)              | 5 (20.8)                | 10 (12.7)        | 0.333†   |
| Indians                                | 8 (7.8)                | 1 (4.2)                 | 7 (8.9)          | 0.677†   |
| Others                                 | 11 (10.7)              | 6 (25.0)                | 5 (6.3)          | 0.018†   |
| BMI, mean (sd)                         | 21.5 (3.7)             | 21.5 (3.8)              | 21.4 (3.7)       | 0.949§   |
| TB type, n(%)                          |                        |                         |                  | 0.934†   |
| Pulmonary                              | 73 (70.9)              | 17 (70.8)               | 56 (70.9)        |          |
| Extrapulmonary                         | 19 (18.4)              | 4 (16.7)                | 15 (19.0)        |          |
| Both                                   | 11 (10.7)              | 3 (12.5)                | 8 (10.1)         |          |
| Drug doses (mg), median (range)        |                        |                         |                  |          |
| Isoniazid                              | 300 (200–386§)         | 300 (200–300)           | 300 (200–386§)   | 0.648‡   |
| Rifampicin                             | 600 (257§–600)         | 600 (300–600)           | 600 (257§–600)   | 0.149‡   |
| Pyrazinamide                           | 1250 (643§–2000)       | 1250 (1000–1750)        | 1250 (643§–2000) | 0.590‡   |
| Ethambutol                             | 1000 (400–1600)        | 950 (600–1400)          | 1000 (400–1600)  | 0.204‡   |
| Received hepatotoxic concomitant medications^, n(%) | 22 (21.3) | 5 (20.8) | 17 (21.5) | 1† |
| NIH Grade, n (%)                       |                        |                         |                  |          |
| 0                                      | 0                      | 79 (100)                |                  |          |
| 2                                      | 10 (41.7)              | 0                       |                  |          |
| 3                                      | 13 (54.2)              | 0                       |                  |          |
| 4                                      | 1 (4.2)                | 0                       |                  |          |
| Baseline LFT, median (range)           |                        |                         |                  |          |
| AST (U/L)                              | 22 (14–48)             | 21 (11–69)              |                  |          |
| ALT (U/L)                              | 18 (8–46)              | 18 (6–64)               |                  |          |
| Onset or follow up LFT, median (range) |                        |                         |                  |          |
| AST (U/L)                              | 212 (104–1401)         | 22 (9–42)               |                  |          |
| ALT (U/L)                              | 199.5 (58–684)         | 17 (5–42)               |                  |          |

P < 0.05 was considered statistically significant and was used for the selection of covariates for the subsequent genomic association analysis

*For association between clinical characteristic and case-control status,
†Mann-Whitney U test,
‡Fisher’s exact test,
§each category compared against all others combined,
¶t-test,
₤one patient on renal dialysis received thrice weekly doses of all drugs.
^Hepatotoxic medications considered here include atorvastatin, simvastatin, ibuprofen, clopidogrel, fenofibrate, paracetamol, acarbose, amitriptyline and tolbutamide. These medications were among drugs with likelihood categories A and B in NIH livertox database.
AL: alanine transaminase, AST: aspartate transaminase, BMI: body mass index, INH-DILI: isoniazid-induced liver injury, LFT: liver function test, NIH: National Institute of Health, mg: milligram, sd: standard deviation, TB: tuberculosis

https://doi.org/10.1371/journal.pone.0186200.001
Table 2. Pharmacogenomic association of NAT2 variants in the Singaporean population.

| Gene   | SNP   | Maj/min | MAF    | Cases     | Ctrl     | OR (95% CI) | P       | Adj P | OR (95% CI) | P       | Adj P | OR (95% CI) | P       | Adj P |
|--------|-------|---------|--------|-----------|----------|-------------|---------|-------|-------------|---------|-------|-------------|---------|-------|
| NAT2   | rs1041983 | G/A    | 0.792 | 0.367     | 6.34 (2.54–15.82) | 0.003       | 5.72 (1.18–27.69) | 0.030 | 0.597 | 13.86 (4.30–44.70) | 0.004 | 0.085 | 4.754 x 10^{-4} |
| NAT2   | rs1495741 | A/G    | 0.167 | 0.551     | 0.21 (0.09–0.52) | 0.024       | 0.10 (0.03–0.33) | 0.004 | 0.004 | 0.25 (0.05–1.21) | 0.085 | 0.901 |
| NAT2   | rs1799929 | G/A    | 0.042 | 0.076     | 0.36 (0.07–1.95) | 0.235       | 0.63 (0.07–1.95) | 0.235 | 0.995 |
| NAT2   | rs179930  | G/A    | 0.5   | 0.222     | 2.85 (1.32–6.16) | 0.008       | 2.16 (0.74–6.28) | 0.159 | 0.980 | 12.00 (2.49–57.84) | 0.002 | 0.069 |
| NAT2   | rs179931  | G/A    | 0.292 | 0.139     | 1.85 (1.20–6.77) | 0.012       | 3.10 (1.05–9.15) | 0.040 | 0.955 | 7.33 (0.96–56.24) | 0.055 | 0.790 |
| NAT2   | rs1801280 | A/G    | 0.042 | 0.095     | 0.30 (0.05–1.62) | 0.161       | 0.30 (0.05–1.68) | 0.169 | 0.982 |

This table shows the association results from logistic regression with gender, PC1 and PC2 as covariates. P values were adjusted for 55 multiple correlated tests using the p_ACT procedure. Significant SNPs (Adj P <0.05) are bolded. Only results for NAT2 are shown here.

*Logistic regression could not be performed due to absence of patients with homozygous variant in either cases or controls.

Adj P: adjusted P value, CI: confidence interval, Ctrl: controls, MAF: minor allele frequency, Maj: major allele, Min: minor allele, OR: odds ratio

https://doi.org/10.1371/journal.pone.0186200.t002

Fig 1. Risk allele frequency of associated NAT2 variants by DILI grade. The frequencies of the risk variants (rs1041983 A, rs1495741 A and NAT2 SA) increase with DILI grade. There was only 1 patient with grade 4 DILI, who was homozygous for the non-risk variants. DILI: drug-induced liver injury, SA: slow acetylators.

https://doi.org/10.1371/journal.pone.0186200.g001
Pharmacogenomic risk prediction analyses

Next, we investigated the accuracy and clinical significance of NAT2 acetylator status and the 2 significant NAT2 SNPs in predicting INH-DILI. Based on the estimated prevalence of serum aminotransferase elevations of 10% [2], we estimated the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of predicting INH-DILI at a prevalence of 10% from NAT2 SA status to be 75%, 78%, 28% and 97%, respectively. Interestingly, the 2 significant NAT2 SNPs also demonstrated similar performance measures, though rs1041983 had slightly lower sensitivity but higher specificity and PPV (Fig 2). As PPV and NPV are dependent on prevalence of the outcome, we also calculated these values for a range of prevalence from 5–20%. While PPV varied considerably (16–47%), NPV was within a narrow range of 93–98% (S6 Table). The population attributable fraction (PAF) and number needed to test (NNT) for NAT2 SA were estimated to be 0.67 and 4.08, respectively.

To examine if NAT2 significantly improves INH-DILI prediction over clinical factors, we then compared the predictive accuracy of a model using clinical variables alone to models that

Fig 2. Clinical validity of NAT2 acetylator status and significant SNPs. Prevalence of 10% is assumed and the risk genotypes for all variants were used for the calculation of clinical validity measures. For both rs1041983 and rs1495741, the homozygous AA genotype is the risk genotype since GA/GG is protective. DOM: dominant, NPV: negative predictive value, PPV: positive predictive value, REC: recessive, SA: slow acetylators.

https://doi.org/10.1371/journal.pone.0186200.g002
included NAT2 acetylator status using receiver operating characteristic (ROC) curves (Fig 3) and Youden’s index. The addition of NAT2 acetylator status provided significantly better prediction over a model with clinical variables alone (area under the curve (AUC) = 0.863 vs. 0.766, respectively, p = 0.027) (Fig 3). We also assessed the additional contributions of rs1041983 and rs1495741 individually as a comparison to NAT2 acetylator status. Models with clinical factors and the 2 SNPs separately also performed similarly, with AUCs of 0.861 (rs1495741) and 0.853 (rs1041983) (S5 Fig). Interestingly, both models with clinical factors and rs1495741 or rs1041983 were significantly better than clinical factors alone (p = 0.029 and 0.038, respectively), but not significantly different from one with clinical factors and NAT2 acetylator status (p = 0.678 and 0.592, respectively). The Youden’s indexes for clinical factors alone, clinical and NAT2 acetylator status, rs1495741 or rs1041983 were 0.500, 0.698, 0.672 and 0.656, respectively.

We further explored the correlation between the 2 SNPs and NAT2 acetylator status in order to determine how well these SNPs tag NAT2 acetylator status in the Singaporean population.
populations. We found that the rs1495741 AA genotype had almost complete concordance (98.1%) with the SA phenotype (S7 Table).

**Discussion**

Here we assessed the association of previously identified pharmacogenomic biomarkers for INH-DILI in a multiethnic Singaporean population. The major findings of this study are that we confirmed the association for 2 NAT2 variants and NAT2 SA status with INH-DILI in this population for the first time. The effect size of 9.98 (95% CI: 3.32–33.8) that we observed was larger than the pooled ORs of 3.1 (95% CI: 2.47–3.88) and 3.08 (95% CI: 2.29–4.15) in prior meta-analyses, although the 95% CIs overlap [12,13]. The effect size we found was also similar to that reported in some studies in Japanese and Iranian populations [17,22,41]. This is the first study to report on the association of NAT2 variants and INH-DILI in a Singaporean population, and adds to the body of literature on the importance of this marker as a predictor of INH-DILI. We also demonstrate the potential clinical utility of NAT2 genotyping for INH-DILI prediction in these Southeast Asian populations.

Our study had >75% power to detect associations for variants with MAF ≥ 0.15 and allelic OR ≥ 4.5 at a significance level of 0.003 (Bonferroni corrected alpha level for 17 independent SNPs). The MAF of majority of the candidate SNPs outside NAT2 (except TNF rs1800629) were > 0.15, so the lack of replication of these variants in our study was likely because the true effect sizes were too small to be detected.

We further demonstrated the clinical validity of testing for NAT2 variants for the prediction of INH-DILI in patients receiving anti-TB drugs. Based on the effect size in our study, NAT2 is an effective test for ruling out INH-DILI if patients are found to not have SA status, owing to the high NPV. Importantly, the NPV is robust to uncertainties in the INH-DILI prevalence. This is potentially clinical significant, as it suggests that patients found to be non-SA could safely undergo treatment with INH with limited monitoring for DILI and high confidence that INH-DILI would not occur. Conversely, patients with SA status would likely benefit from closer surveillance for the development of DILI. Two-thirds of INH-DILI cases can be attributed to the presence of NAT2 SA, and about 4 patients would need to be tested to prevent one case, if followed by an intervention that effectively mitigates the risk of INH-DILI. NAT2 was also shown to significantly improve INH-DILI prediction over clinical factors alone. To our knowledge, this is the first study to include an assessment of the clinical validity of NAT2 for INH-DILI, which is a necessary step towards clinical implementation of this drug-gene pair. Future studies will be able to formally assess the cost-effectiveness of NAT2 genotyping based on the clinical validity of the test as determined in our study.

Our results add to the body of evidence supporting the use of NAT2 acetylator status for prediction of INH-DILI. For individuals found to be at high genetic risk of INH-DILI, dose-adjustment based on NAT2 genotype may represent a strategy to reduce the risk of DILI. A clinical trial of pharmacogenomic-guided INH dosing in a Japanese population demonstrated a significant reduction in INH-DILI when NAT2 SA were administered a reduced, without compromising treatment effectiveness [42]. Another pilot study linking NAT2 genotype and INH serum concentration also supports pharmacogenetic-guided INH dosage regimens [43]. Further work is needed to establish evidence-based genotype specific clinical recommendations for NAT2 [44].

While NAT2 acetylator status has been consistently associated with INH-DILI, results for individual NAT2 SNPs are much more variable. For example, rs1799930 was significantly associated with INH-DILI in some studies [23,27,32,34,35,45,46] but not others [24,29,31,47,48]. One possibility for this observation could be the imperfect tagging of NAT2 acetylator status.
by a single SNP, which we also observed in our study. A tag SNP for NAT2 acetylator status (rs1495741) was identified in a bladder cancer GWAS in Europeans [49]. Other studies have also found high concordance between rs1495741 and NAT2 acetylator status in Asians, Europeans and admixed Americans, but not in Africans [15,50]. Consistent with these observations, we also found high concordance between rs1495741 and NAT2 acetylator status in our cohort. The presence of African Americans in the study of Hein et al. may explain the high misclassification rate for rs1495741 reported in that study [14]. Taken together, our results suggest rs1495741 could be used to tag NAT2 SA with high accuracy in Southeast Asian populations.

There are several limitations to our study. Firstly, we did not have sufficient Malay and Indian patients to thoroughly explore the ethnic specificity of the associations in those subgroups. However, it appears that the effect is consistent across the 3 major ethnic groups though the associations in Malay and Indian populations alone did not reach statistical significance due to small sample size. Secondly, some variants previously associated with INH-DILI were not included due to the nature of our genotyping assay. However, a review of these excluded variants found none of sufficient priority in terms of strength of evidence. Most variants were from single studies or were not significant in meta-analyses (GSTM1 and CYP2E1 rs6413432). We therefore chose not to genotype or impute them in our study. Thirdly, our study focused on specific candidate gene variants, and did not identify new genetic variants for INH-DILI. Future studies which combine multiple cohorts will be needed to perform GWAS for INH-DILI with appropriately powered sample sizes. Lastly, it was not possible to identify definitively the causative drug for the DILI as patients were taking 4 drugs simultaneously, but INH has the highest hepatotoxic potential among the drugs. All DILI cases were re-challenged and 80% of them tolerated INH upon re-challenge and completed their treatment. However, this is in line with reports that up to 80% of suspected INH-DILI cases tolerate reintroduction of treatment after the resolution of the initial injury [2].

In conclusion, we have reestablished the association between NAT2 SA and INH-DILI in a Singaporean population and demonstrated its clinical validity in prediction of INH-DILI. Clinical studies and pharmacoeconomic analyses are now needed to support the clinical implementation of NAT2 pharmacogenetic testing for INH-DILI in Singapore.

Material and methods

Recruitment and detailed clinical characterization of patients

Cases of INH-DILI were defined as patients with Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade 2 and above for levels of aspartate transaminase (AST) and/or alanine transaminase (ALT) (i.e. >2.5x upper limit of normal (ULN)) [51], and were recruited retrospectively. Patients with active TB from 2014 to January 2016 were identified from the National TB registry, and those treated at the TB Control Unit (TBCU) in Tan Tock Seng Hospital were screened. Potential cases were shortlisted if their TB treatment was interrupted because of drug-induced liver reactions. A trained research nurse reviewed the medical records of these patients to determine if they met the inclusion criteria: i) undergoing treatment of active TB, ii) on anti-TB drugs which should include INH, rifampicin, pyrazinamide, and ethambutol, and iii) 21 to 95 years old. Patients were excluded if they had any of the following: i) unable to provide informed consent, ii) pregnant or breast feeding, iii) alcoholism, iv) chronic hepatitis B or C and other types of hepatitis or v) HIV co-infection. There was no limitation on the co-administration of drugs unrelated to TB treatment but we also assessed the possible contribution of potentially hepatotoxic drugs. For this purpose, drugs classified in categories A (>50 published reports) and B (13–50 published reports) for likelihood of causing
DILI were considered hepatotoxic [52,53]. Eligible cases were then recalled for informed consent and blood sampling.

Control patients were recruited from October 2015 to April 2016 and were eligible if they had completed 6 months of TB treatment in TBCU with no symptoms of hepatotoxicity during treatment, and had normal post-treatment liver function tests (LFTs). All patients received their anti-TB treatment under direct observed therapy and all controls were adherent to therapy.

Blood or saliva was collected from recruited patients and deoxyribonucleic acid (DNA) extracted using the prepIT-L2P kit (Genotek, Ottawa, Canada) and DNeasy Blood & Tissue Kit (Qiagen GmbH, Hilden, Germany), respectively, according to manufacturer’s instructions. Clinical data were collected from all patients, including demographics, drug treatment details, baseline and follow-up LFTs, which occurred at the point of onset for cases or 6 months after treatment initiation for controls. All patients gave their written informed consent and the study was approved by the National Healthcare Group Domain Specific Review Board.

Genotyping and quality control

All samples were genotyped using the Illumina HumanOmniExpress-24 beadchip v1.2 (Illumina, San Diego, CA). To verify the accuracy of all genotyping results, multiple positive and negative (water) controls as well as duplicate samples were included in the assays. No genotyping errors were detected with the use of these controls. To remove any samples or SNPs with genotyping failure or errors, QC filtering was performed to remove samples with high IBS, discordant sex, excess heterozygosity or call rate <95%, and SNPs with call rate <95%, deviation from HWE in Chinese (p <1.0 x 10^{-6}). All Chinese patients (cases and controls) were chosen as the population for HWE testing to remove SNPs with genotyping errors in view of the presence of population mixture and small sample size. PCA was performed and we included PCs as covariates to adjust for population structure. Cluster plots of SNPs reaching statistical significance were inspected visually.

Candidate SNP selection

A comprehensive literature search was performed via PubMed to identify previous pharmacogenomic studies on INH-DILI using the key words (isoniazid OR tuberculosis) AND (liver injury OR hepatitis OR hepatotoxicity) AND (pharmacogen* OR gene OR genetic OR allele OR variant) on 7 Oct 2016. We also searched the publication list for INH in the Pharmacogenomics Knowledgebase (PharmGKB) [54], a publicly available resource with manually curated knowledge on the impact of human genetic variation on drug response, to supplement the primary literature search. Genetic variants that have been found to be associated with INH-DILI at least once were then screened for their allele frequencies in Chinese, Malays and Indians using the Singapore Genome Variation Project database [40] or 1000 genomes (Southern Han Chinese (CHS) and Sri Lankan Tamil from the UK (STU), which has previously been shown to be very similar to Singaporean Indians) [55,56], and their presence in the genotyping panel.

Statistical analysis

The primary study was designed as a case control study comparing a group of adult TB patients with INH-DILI with a drug matched control group without INH-DILI. We compared clinical characteristics between cases and controls to identify any that were significantly different (P < 0.05) between the 2 groups using t-test, Mann-Whitney U test, chi-square test or Fisher’s exact test as appropriate. The associations between the candidate SNPs and INH-DILI were tested using logistic regression under different genetic models (additive/dominant/
 recessive), with gender and the first 2 PCs as covariates. Results were presented as P-values and OR with 95% CIs. To adjust for multiple testing, we calculated adjusted P-values using $P_{ACT}$, a computationally efficient method which takes into account correlation due to linkage disequilibrium and different genetic models [57]. Adjusted P-values of $<0.05$ were considered statistically significant and the genetic model with the lowest P-value was used for further analyses. The distribution of the individual alleles and genotypes between cases and controls for the associated variants were also assessed and the P-values and ORs with 95% CIs for each of the respective alleles and genotypes estimated using Fisher’s exact test.

We inferred NAT2 acetylator status using a 4 SNP panel (rs1801280, rs1799930, rs1799931 and rs1801279), where RA were homozygous common for all SNPs, IA were heterozygous for any SNP and SA were heterozygous for $\geq$ 2 SNPs or homozygous variant for at least 1 SNP [14]. rs1801279 was not included in our candidate SNP list as it was not present on our genotyping panel and expected to be monomorphic in Chinese, Malays and Indians (S1 Table). We therefore considered this SNP to be homozygous wild type in our cohort. The association between NAT2 acetylator status and INH-DILI was tested using logistic regression with covariates included, as well as Fisher’s exact test. All statistical tests performed were 2-sided.

To evaluate the clinical utility of NAT2 acetylator status and associated SNPs, we calculated the sensitivity, specificity, and estimated the PPV and NPV using Baye’s theorem assuming a prevalence of 10% [58]. To take into account uncertainty in the estimation of INH-DILI prevalence, we also performed a sensitivity analysis for the PPV and NPV over a range of prevalences (5–20%). We further calculated the PAF and NNT to detect 1 case of INH-DILI according to the following formulas,

$$PAF = \frac{IP_t - IP_o}{IP_t}$$

(1)

$$NNT = \frac{1}{ARR}$$

(2)

where $IP_t$ = incidence proportion in the total population and $IP_o$ = incidence proportion in the unexposed (IA/RA group), and $ARR = \text{absolute risk reduction} = IP_t - IP_t$—incidence proportion in exposed (SA).

Finally, we demonstrated the clinical utility of NAT2 acetylator status and SNPs over clinical variables using ROC analysis and compared the AUCs for prediction models based on clinical factors (“clinical”) and “clinical +genetic” risk factors using DeLong’s test [59]. To estimate the additional contribution of genetic factors in a clinical setting, we used all known clinical factors relevant (not invariant) in our cohort, which were age, gender and self-reported ethnicity. The performance of each prediction model (overall sensitivity and specificity) was calculated using AUC of the ROC curves as well as Youden’s index (or Youden’s J statistic), where $J = \text{sensitivity} + \text{specificity} - 1$. The maximum value of $J$ along all points on the ROC curve represents the optimum sensitivity and specificity [60]. All analyses were conducted in PLINK v1.9 [61] or R version 3.3.3 [62].

**Supporting information**

**S1 Fig. Patient recruitment flowchart.** Flowchart showing numbers of patients screened, excluded and enrolled for INH-DILI cases and controls.

DILI: drug-induced liver injury, INH: isoniazid, LFT: liver function tests, TB: tuberculosis, TBCU: Tuberculosis control unit, tx: treatment, +: Still attending TBCU for treatment.
S2 Fig. Principal components analysis plot. Plot of the first 2 principal components. PC1 separates the Indians from the other ethnicities while PC2 separates the Chinese from the Malays.

S3 Fig. Scree plot. Plot of eigenvalues for the first 20 principal components. The first 2 PCs explained more variance than the rest of the PCs.

S4 Fig. Cluster plots for associated NAT2 SNPs. Cluster plots for (a) rs1041983 and (b) rs1495741 shows clear clustering of genotypes.

S5 Fig. Predictive value of NAT2 acetylator status and SNPs. Predictive values were evaluated using receiver operating characteristic (ROC) curves and expressed as area-under-curve (AUC), which is a summary measure of the sensitivity and specificity. The clinical model (clin) consists of age, gender and self-reported ethnicity. DOM: dominant, REC: recessive, SA: slow acetylators.

S1 Table. Selection of candidate SNPs.

S2 Table. Pharmacogenomic association of candidate variants in the Singaporean population.

S3 Table. Association results for candidate SNPs with INH-DILI severity.

S4 Table. Allelic and genotypic distributions of NAT2 associated variants.

S5 Table. Association of NAT2 acetylator status and SNPs within ethnic groups.

S6 Table. Clinical validity of NAT2 acetylator status and 2 significant SNPs by prevalence.

S7 Table. Correlation between NAT2 SNPs and acetylator status.

Acknowledgments

The authors would like to thank all patients who participated in the study. We also thank Ms Sek Onn Lam and Ms Beng Choo Ng for their help in patient recruitment, Ms Madeline Kwek for her assistance in processing the patient samples.

Author Contributions

Conceptualization: Liam R. Brunham.

Data curation: Sze Ling Chan, Folefac Aminkeng, Shengnan Jin, Marie Loh.

Formal analysis: Sze Ling Chan, Shengnan Jin.

Funding acquisition: Liam R. Brunham.
**Investigation:** Sze Ling Chan, Angeline Poh Gek Chua, Cynthia Bin Eng Chee, Shengnan Jin, Suay Hong Gan.

**Methodology:** Sze Ling Chan, Angeline Poh Gek Chua, Folefac Aminkeng, Shengnan Jin, Marie Loh, Yee Tang Wang, Liam R. Brunham.

**Project administration:** Yee Tang Wang, Liam R. Brunham.

**Resources:** Sze Ling Chan, Shengnan Jin, Yee Tang Wang, Liam R. Brunham.

**Supervision:** Marie Loh, Yee Tang Wang, Liam R. Brunham.

**Visualization:** Sze Ling Chan.

**Writing – original draft:** Sze Ling Chan, Liam R. Brunham.

**Writing – review & editing:** Sze Ling Chan, Angeline Poh Gek Chua, Folefac Aminkeng, Cynthia Bin Eng Chee, Shengnan Jin, Marie Loh, Suay Hong Gan, Yee Tang Wang, Liam R. Brunham.

**References**

1. World Health Organization. Global Tuberculosis Report 2016 [Internet]. 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1

2. National Institutes of Health. Isoniazid [Internet]. Clinical and Research Information on Drug-Induced Liver Toxicity. [cited 2016 Nov 8]. https://livertox.nlm.nih.gov/Isoniazid.htm

3. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab. 2007 Dec; 8 (8):839–51. PMID: 18220565

4. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A Fresh Look at the Mechanism of Isoniazid-Induced Hepatotoxicity. Clin Pharmacol Ther. 2011 Jun 16; 89(6):911–4. https://doi.org/10.1038/clpt.2010.355 PMID: 21412230

5. Nanashima K, Mawatari T, Tahara N, Higuchi N, Nakaura A, Inamine T, et al. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinb). 2012 May; 92(3):253–9.

6. Wang J, Chen R, Tang S, Lv X, Wu S, Zhang Y, et al. Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study. PLoS One. 2015; 10(3):e0118662. https://doi.org/10.1371/journal.pone.0118662 PMID: 25789467

7. Chang J-C, Liu EH, Lee C-N, Lin Y-C, Yu M-C, Bai K-J, et al. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J Tuberc Lung Dis. 2012; 16(3):376–8. https://doi.org/10.5588/ijtld.11.0404 PMID: 2230213

8. Huang Y-S, Su W-J, Huang Y-H, Chen C-Y, Chang F-Y, Lin H-C, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007 Jul; 47(1):128–34. https://doi.org/10.1016/j.jhep.2007.02.009 PMID: 17400324

9. Chen R, Zhang Y, Tang S, Lv X, Wu S, Sun F, et al. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study. J Clin Pharm Ther. 2015 Feb; 40 (1):110–5. https://doi.org/10.1111/jcpt.12211 PMID: 25250564

10. Leiro-Fernández V, Valverde D, Vázquez-Galliardo R, Constaña-Caramés L, Del Campo-Pérez V, Fernández-Villar A. HLA-DQ B1*0201 and A1*0102 Alleles Are Not Responsible for Antituberculosis Drug-Induced Hepatotoxicity Risk in Spanish Population. Front Med. 2016; 3:34.

11. Kim S-H, Kim S-H, Yoon HJ, Shin DH, Park SS, Kim Y-S, et al. TNF-a genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver Int. 2012 May; 32(5):809–14. https://doi.org/10.1111/j.1478-3231.2011.02697.x PMID: 22151084

12. Du H, Chen X, Fang Y, Yan O, Xu H, Li L, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013 May 1; 40(5):3591–6. https://doi.org/10.1007/s11033-012-2433-y PMID: 23277997

13. Shi J, Xie M, Wang J, Xu Y, Liu X. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics. 2015 Dec; 16(18):2083–97. https://doi.org/10.2217/pgs.15.144 PMID: 26616266
14. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012 Jan; 13(1):31–41. https://doi.org/10.2217/pgs.11.122 PMID: 22920306

15. Ho H-T, Wang T-H, Hsiong C-H, Perng W-C, Wang N-C, Huang T-Y, et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics. 2013 Apr; 23(4):200–7. https://doi.org/10.1097/FPC.0b013e32835e95e1 PMID: 23407048

16. Wang F-J, Wang Y, Niu T, Lu W-X, Sandford AJ, He J-Q. Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies. J Clin Pharm Ther. 2016 Jun; 41(3):334–40. https://doi.org/10.1111/jcpt.12388 PMID: 27062377

17. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000 Mar; 4(3):256–61. PMID: 10751073

18. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 “null” mutation. J Gastroenterol Hepatol. 2001 Sep; 16(9):1033–7. PMID: 11995069

19. Huang Y-S, Chen H-D, Su W-J, Wu J-C, Chang S-C, Chiang C-H, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. 2003 Apr; 37(4):924–30. https://doi.org/10.1038/sj.hgp.300144 PMID: 12668988

20. Shimizu Y, Dobashi K, Mita Y, Endou K, Moriya S, Osano K, et al. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb). 2006 Sep; 86(5):374–81.

21. Cho H-J, Koh W-J, Ryu Y-J, Ki C-S, Nam M-H, Kim J-W, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007 Nov; 87(6):551–6.

22. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol. 2007 Dec 7; 13(45):6003–8.

23. Kim S-H, Kim S-H, Bahn J-W, Kim Y-K, Shin E-S, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009 Nov; 10(11):1767–79. https://doi.org/10.2217/pgs.09.100 PMID: 19891553

24. Lee S-W, Chung LS-C, Huang H-H, Chuang T-Y, Liou Y-H, Wu LS-H. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2010 May; 14(5):622–6. PMID: 20392357

25. Bosa PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyltransferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011 Feb; 26(2):312–8. https://doi.org/10.1111/j.1440-1746.2010.06355.x PMID: 21261721

26. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo. 2011; 25(5):803–12. PMID: 21753138

27. An H-R, Wu X-Q, Wang Z-Y, Zhang J-X, Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatitis in Chinese patients. Clin Exp Pharmacol Physiol. 2012 Jun; 39(6):535–43. https://doi.org/10.1111/j.1440-1681.2012.05713.x PMID: 22506592

28. Tang S, Lv X, Zhang Y, Wu S, Yang Z, Xia Y, et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort. PLoS One. 2013; 8(2):e57526. https://doi.org/10.1371/journal.pone.0057526 PMID: 23460870

29. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol. 2013 Aug; 28(8):1368–74. https://doi.org/10.1111/jgh.12194 PMID: 23875638

30. Rana S V, Sharma SK, Ola RP, Kamboj JK, Mallik A, Morya RK, et al. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians. J Clin Pharm Ther. 2014 Feb; 39(1):91–6. https://doi.org/10.1111/jcpt.12105 PMID: 24188272

31. Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, et al. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uygur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One. 2014; 9(1):e85905. https://doi.org/10.1371/journal.pone.0085905 PMID: 24465778
32. Singh M, Gupta VH, Amarapurkar DN, Joshi JM, Baijal R, Ramegowda PH, et al. Association of genetic variants with anti-tuberculosis drug induced hepatotoxicity; a high resolution melting analysis. Infect Genet Evol. 2014 Apr; 23:42–8. https://doi.org/10.1016/j.meegid.2014.01.027 PMID: 24491431

33. Singla N, Gupta D, Birbain N, Singh J. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb). 2014 May; 94(3):293–8.

34. Mishra S, Daschakraborty S, Shukla P, Kapoor P, Aggarwal R. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to anti-tuberculosis drug hepatotoxicity in an Indian population. Natl Med J India. 26(5):260–5. PMID: 25017831

35. Yuliwulan dari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016 Jun; 61(6):533–7. https://doi.org/10.1038/jhg.2016.10 PMID: 26911349

36. Mushiroda T, Yanai H, Yoshiyama T, Sasaki Y, Okumura M, Ogata H, et al. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Hum genome Var. 2016; 3:16014. https://doi.org/10.1038/hgv.2016.14 PMID: 27340556

37. Roy B, Ghosh SK, Sutradhar D, Sarkar N, Mazumder S, Barman S. Predisp osition of antituberculosis...
50. Suarez-Kurtz G, Fuchshuber-Moraes M, Struchiner CJ, Parra EJ. Single nucleotide polymorphism coverage and inference of N-acetyltransferase-2 acetylator phenotypes in worldwide population groups. Pharmacogenet Genomics. 2016 Aug; 26(8):363–9. https://doi.org/10.1097/FPC.0000000000000225 PMID: 27136043

51. National Institutes of Health. Severity Grading in Drug Induced Liver Injury [Internet]. Clinical and Research Information on Drug-Induced Liver Toxicity. [cited 2016 Nov 8]. https://livertox.nlm.nih.gov/Severity.html

52. National Institutes of Health. Categorization of the likelihood of drug induced liver injury [Internet]. Clinical and Research Information on Drug-Induced Liver Toxicity. [cited 2017 Jan 13]. https://livertox.nih.gov/DrugCategory.html

53. Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci. 2016 Feb 6; 17(2):224. https://doi.org/10.3390/ijms17020224 PMID: 26861310

54. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct; 92(4):414–7. https://doi.org/10.1038/clpt.2012.96 PMID: 22992668

55. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56–65. https://doi.org/10.1038/nature11632 PMID: 23128226

56. Chan SL, Samaranayake N, Ross CJD, Toh MT, Carleton B, Hayden MR, et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics. 2016 Jan; 26(1):28–39. https://doi.org/10.1097/FPC.0000000000000182 PMID: 26444257

57. Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet. 2007 Dec; 81(6):1158–68. https://doi.org/10.1086/522036 PMID: 17966093

58. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994 Jul 9; 309(6947):102. PMID: 8038641

59. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep; 44(3):837–45. PMID: 3203132

60. Youden WJ. Index for rating diagnostic tests. Cancer. 1950 Jan; 3(1):32–5. PMID: 15405679

61. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015; 4:7. https://doi.org/10.1186/s13742-015-0047-8 PMID: 25722852

62. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. R Foundation for Statistical Computing. 2014. http://www.R-project.org